遗传变异与非酒精性脂肪肝病的研究进展

摘要/Abstract

摘要： 非酒精性脂肪肝病是遗传-环境-代谢相关性疾病,是西方国家最常见的慢性肝病,在我国是继病毒性肝炎后第二位常见肝病,常与肥胖、2型糖尿病、血脂紊乱、高血压等代谢综合征(metabolic syndrome, MS)症状并存,近年来其患病率逐年增加,已成为引起慢性肝病及血清氨基酸转移酶水平升高的主要原因之一。近几年非酒精性脂肪肝病与遗传基础的关系越来越受到关注。本文综述了脂肪酸代谢、胰岛素抵抗、氧化应激、细胞因子等与非酒精性脂肪肝病相关的遗传变异的研究进展。

关键词: 非酒精性脂肪肝病, 遗传变异, 基因, 基因多态性

Abstract: Nonalcoholic fatty liver disease is a group of heredity-environment-metabolism stress disease. It is the most common chronic liver disease in the western country and the second common liver disease after viral hepatitis in our country. Nonalcoholic fatty liver disease is considered as a component of metabolism syndrome, which consists of obesity, type II diabetes mellitus, dyslipidemia and hypertension. Nonalcoholic fatty liver disease have been becoming a common cause of chronic liver diseases and transaminase abnormality. Recently, the genetic basis of Nonalcoholic fatty liver disease is attracting more and more attention. The studies between nonalcoholic fatty liver and genetic variations affecting fatty acid metabolism, insulin resistance, oxidative stress and so on were sumnarized.

Key words: Nonalcoholic fatty liver disease, Genetic variation, Gene, Gene polymorphism

中图分类号:

R575

景贤, 李慧, 邓晓兰, 欧阳冬生. 遗传变异与非酒精性脂肪肝病的研究进展[J]. 中国临床药理学与治疗学, 2012, 17(8): 950-956.

JING Xian, LI Hui, DENG Xiao-lan, OUYANG Dong-sheng. Study on the relationship between genetic variation and nonalcoholic fatty liver disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 950-956.

参考文献

[1] Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease[J]. Best Pract Res Clin Gastroenterol,2010, 24(5):695-708.
[2] 胡翠兰, 王军, 彭浩, 等. 二氯乙酸二异丙胺片治疗非酒精性脂肪肝病40例[J]. 医药导报,2009, 28(11):1460-1461.
[3] Yang Z, Wang X, Wen J, et al. Prevalence of non-alcoholic fatty liver disease and its relation to hypoadiponectinaemia in the middle-aged and elderly Chinese population[J]. Arch Med Sci,2011, 7(4):665-672.
[4] Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity[J]. Hepatology,2004, 40(6): 1387-1395.
[5] Browning JD, Kumar KS, Saboorian MH, et al. Ethnic differences in the prevalence of cryptogenic cirrhosis[J]. Am J Gastroenterol,2004, 99(2): 292-298.
[6] Caldwell SH, Harris DM, Patrie JT, et al. Is NASH underdiagnosed among African Americans [J] ?Am J Gastroenterol,2002, 97(6): 1496-1500.
[7] Day CP, James DF. Steatohepatitis: a table of two "hit" [J] ?Gastroenterology, 1998, 114(4): 842-845.
[8] Namikawa C, Shu-Ping Z, Vyselaar JR, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis[J]. J Hepatol,2004, 40(5): 781-786 .
[9] Oliveira CP, Stefano JT, Cavaleiro AM, et al. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol,2010, 25(2): 357-361.
[10] Hashemi M, Hoseini H, Yaghmaei P, et al. Association of Polymorphisms in Glutamate-Cysteine Ligase Catalytic Subunit and Microsomal Triglyceride Transfer Protein Genes with Nonalcoholic Fatty Liver Disease[J]. DNA Cell biol,2011, 30(8): 569-575.
[11] Song J, da Costa KA, Fischer LM, et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD)[J]. FASEB J,2005, 19(10): 1266-1271.
[12] Dong H, Wang J, Li C, et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population[J]. J Hepatol, 2007, 46(5): 915-920 .
[13] Zhang B, Xie W, Krasowski MD. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics[J]. Pharmacogenomics,2008, 9(11): 1695-1709 .
[14] Sookoian S, Castano GO, Burgueno AL, et al. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease[J]. Pharmacogenet Genomics,2010, 20(1):1-8 .
[15] Everett L, Galli A, Crabb D. The role of hepatic peroxisome proliferator-activated receptors(PPARs) in health and disease[J]. Liver, 2000, 20(3):191-199.
[16] Ferré P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity[J]. Diabetes,2004, 53(Suppl):S43-50.
[17] Chen S, Li Y, Li S, et al. A Val227Ala substitution in the peroxisome proliferator activated receptor alpha(PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio[J]. Gastroenterol Hepatol,2008, 23(9):1415-418.
[18] Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease[J]. N Engl J Med,2010, 362(12): 1082-1089 .
[19] Kozlitina J, Boerwinkle E, Cohen JC, et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance[J]. Hepatology, 2011, 53(2): 467-474.
[20] Maddux BA, Goldfine ID. Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor -subunit[ J]. Diabetes,2000, 49(1): 13-19.
[21] Carulli L, Canedi I, Rondinella S, et al. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis[J]. Dig Liver Dis,2009, 41(11): 823-828 .
[22] Dongiovanni P, Valenti L, Rametta R, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease[J]. Gut,2010, 59(2): 267-273.
[23] Johannes W Rey, Andrea Noetel, Aline Hardt, et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases[J]. World J Gastroenterol, 2010, 16(46): 5830-5837.
[24] AC Gupta, AK Chaudhory, Sukriti, et al. Peroxisome proliferators-activated receptor γ2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients[J]. Hepatol Int, 2010, 5(1): 575-580.
[25] Dongiovanni P, Rametta R, Fracanzani AL, et al. Lack of association between peroxisome proliferator-activated receptors alpha and gamma-polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study[J]. BMC Gastroenterol,2010, 10:102-108.
[26] Yang Z, Wen J, Li Q, et al. PPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population[J]. Molecular and Cellular Endocrinology, 2012, 348(1):255-259.
[27] Musso G, Gambino R, De Michieli F, et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH[J]. Hepatology, 2008, 47(4): 1167-1177.
[28] Nobili V, Daly AK, Al-Serri A, et al. The mitochondrial superoxide dismutase 2 (SOD2) targeting sequence polymorphism is associated with fibrotic NAFLD: consistent evidence from case-control and intra-familial allelic association studies[J]. Hepatology, 2007, 46(4): 760A-760A.
[29] Dongiovanni P, Rametta R, Fracanzani AL, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies[J]. Journal of Hepatology,2012, 56(2):448-454.
[30] Chen Y, Yang Y, Miller ML, et al. Hepatocyte-specific GCLC deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure[J]. Hepatology, 2007, 45(5): 1118-1128 .
[31] Oliveira CP, Stefano JT, Cavaleiro AM, et al. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol,2010, 25(2): 357-361 .
[32] Lin YC, Chang PF, Hu FC, et al. Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease[J]. Pediatrics,2009, 124(6): e1221-e1227.
[33] Kowdley KV. The role of iron in nonalcoholic fatty liver disease: the story continues[J]. Gastroenterology, 2010, 138(3): 817-819 .
[34] George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis[J]. Gastroenterology,1998,114(2): 311-318 .
[35] Nelson JE, Bhattacharya R, Lindor KD, et al. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis[J]. Hepatology,2007, 46(3): 723-729 .
[36] Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2010, 138(3): 905-912 .
[37] Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease[J]. Gastroenterology,2002, 122(2): 274-280.
[38] Tokushige K, Takakura M, Tsuchiya-Matsushita N, et al. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis[J]. J Hepatol,2007, 46(6): 1104-1110 .
[39] Wong VW, Wong GL, Tsang SW, et al.Genetic polymorphisms of adiponectin and tumor necrosis factor alpha and nonalcoholic fatty liver disease in Chinese people[J]. J Gastroenterol Hepatol, 2008, 23(6): 914-921.
[40] Dixon JB, Bhathal PS, Jonsson JR, et al. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese[J]. J Hepatol,2003, 39(6): 967-971 .
[41] Yoneda M, Hotta K, Nozaki Y, et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease[J]. Liver Int, 2009, 29(7): 1078-1085 .
[42] Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option [J] ? Adv Ther,2008, 25(11): 1141-1174 .
[43] Starkel P, Sempoux C, Leclercq I, et al. Oxidative stress, KLF6 and transforming growth factor-b up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats[J]. J Hepatol,2003, 39(4): 538-546 .
[44] Miele L, Beale G, Patman G, et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease[J]. Gastroenterology,2008, 135(1): 282-291 e281 .
[45] Espino A, Villagrán A, Vollrath V, et al. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease[J]. Ann hepatolo,2011, 10(4): 493-501.
[46] Sookoian S, Castaño G, Gemma C, et al. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease[J]. World J Gastroenterolo,2007, 13(31): 4242-4248.
[47] Jarvelainen HA, Orpana A, Perola M, et al. Promotor polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease[J]. Hepatology,2001, 33(5): 1148-1153.
[48] Day CP, Leathart J, McTernan P, et al. Genetic evidence for a role of gut flora in the pathogenesis of NASH in humans[J]. Hepatology,2006, 44(Suppl 1): 261A- 261A.
[49] Romeo S, Sentinelli F, Cambuli VM, et al. The 148M allele of the PNPLA3 gene is associated with indices ofliver damage early in life[J]. J Hepatol,2010, 53(2): 335-338.
[50] Lynne E,Wagenknecht, Nicholette D,et al. Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study[J]. Liver International,2011, 31(3): 412-416.
[51] Krawczyk M, Grünhage F, Zimmer V, et al. Variant adiponutrin (PNPLA3) represents a commonfibrosis risk gene: Non-invasive elastography-based study in chronic liver disease[J]. J Hepatol,2011, 55(2): 299-306.